InnovAge (INNV) Moves 7.8% Higher: Will This Strength Last?
Summarize this article with:
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks InnovAge (INNV) Moves 7.8% Higher: Will This Strength Last? December 16, 2025 — 07:36 am EST Written by Zacks Equity Research for Zacks-> InnovAge Holding Corp. INNV shares rallied 7.8% in the last trading session to close at $5.82. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.6% gain over the past four weeks.InnovAge witnessed a strong price rise on investors’ optimism surrounding its robust revenue growth in fiscal first quarter 2025. Total revenues of $236.1 million, increased approximately 15.1% year over year in fiscal first quarter compared to year ago period. In addition, net income was $7.7 million compared to year ago quarter’s net loss of $5.7 million. This company is expected to post quarterly earnings of $0.04 per share in its upcoming report, which represents a year-over-year change of +140%. Revenues are expected to be $228.16 million, up 9.2% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For InnovAge, the consensus EPS estimate for the quarter has been revised 20% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on INNV going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>InnovAge is a member of the Zacks Medical Services industry. One other stock in the same industry, Danaher DHR, finished the last trading session 1% higher at $228.53. DHR has returned 2.3% over the past month. For Danaher, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $2.14. This represents no change from what the company reported a year ago. Danaher currently has a Zacks Rank of #4 (Sell).
Zacks Naming Top 10 Stocks for 2026 Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational. From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5. Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report InnovAge Holding Corp. (INNV) : Free Stock Analysis ReportDanaher Corporation (DHR) : Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags StocksInvestingHow to Invest Zacks Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com. More articles by this source-> Stocks mentioned INNV DHR More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.